HK1219868A1 - 治疗和防治肠道损伤、紧密连接部功能障碍相关疾病的方法和组合物 - Google Patents

治疗和防治肠道损伤、紧密连接部功能障碍相关疾病的方法和组合物 Download PDF

Info

Publication number
HK1219868A1
HK1219868A1 HK16106374.5A HK16106374A HK1219868A1 HK 1219868 A1 HK1219868 A1 HK 1219868A1 HK 16106374 A HK16106374 A HK 16106374A HK 1219868 A1 HK1219868 A1 HK 1219868A1
Authority
HK
Hong Kong
Prior art keywords
glycerophosphate
composition
exercise
core
enteric coating
Prior art date
Application number
HK16106374.5A
Other languages
English (en)
Chinese (zh)
Inventor
‧克利傑曼
A‧E‧克利杰曼
．韋斯
M．T．韦斯
Original Assignee
普瑞丽芙有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 普瑞丽芙有限公司 filed Critical 普瑞丽芙有限公司
Publication of HK1219868A1 publication Critical patent/HK1219868A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
HK16106374.5A 2013-02-20 2014-02-20 治疗和防治肠道损伤、紧密连接部功能障碍相关疾病的方法和组合物 HK1219868A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361766976P 2013-02-20 2013-02-20
US61/766,976 2013-02-20
US201361827080P 2013-05-24 2013-05-24
US61/827,080 2013-05-24
US201361897672P 2013-10-30 2013-10-30
US61/897,672 2013-10-30
PCT/US2014/017408 WO2014130678A2 (en) 2013-02-20 2014-02-20 Methods and compositions of treating and preventing intestinal injury and diseases related to tight junction dysfunction

Publications (1)

Publication Number Publication Date
HK1219868A1 true HK1219868A1 (zh) 2017-04-21

Family

ID=50240015

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106374.5A HK1219868A1 (zh) 2013-02-20 2014-02-20 治疗和防治肠道损伤、紧密连接部功能障碍相关疾病的方法和组合物

Country Status (9)

Country Link
US (1) US20150374725A1 (https=)
EP (1) EP2958567A2 (https=)
JP (1) JP2016509059A (https=)
KR (1) KR20150141943A (https=)
CN (1) CN105163740A (https=)
AU (1) AU2014218903A1 (https=)
HK (1) HK1219868A1 (https=)
MX (1) MX2015010765A (https=)
WO (1) WO2014130678A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
EP3345591A1 (en) * 2017-01-06 2018-07-11 Oystershell NV Oral dosage form for enhanced solubilization of a poorly soluble active agent and method of preparation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2993837A (en) * 1959-07-13 1961-07-25 Frosst & Co Charles E Enteric coated tablets
US5665415A (en) 1995-07-26 1997-09-09 Akpharma Inc. Composition and method for increasing the pH of acid foods
US20020099037A1 (en) * 2001-01-19 2002-07-25 Akpharma, Inc. Method for alleviating syndromes and conditions of discomfort of the mammalian intestinal and genito-urinary tracts
US7402323B2 (en) 2002-08-21 2008-07-22 Akpharma, Inc. Compositions and methods for treating skin conditions
CN1816324A (zh) * 2003-07-04 2006-08-09 尼克麦德丹麦公司 口服用的含甲状旁腺激素(pth)的药物组合物
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
US20100041630A1 (en) * 2007-02-14 2010-02-18 Prelief Inc. Methods for Treating or Preventing Inflammation Using a Glycerophosphate Salt
US20080220084A1 (en) * 2007-03-09 2008-09-11 Pfantastic Medical Research Institute, Llc Combination therapy for alleviating pain-related conditions
US20100305071A1 (en) * 2007-08-30 2010-12-02 Prelief Inc. Methods for improving healing of an oral lesion using a glycerophosphate salt
WO2009052489A2 (en) * 2007-10-19 2009-04-23 Alba Therapeutics Corporation Novel inhibitors of mammalian tight junction opening

Also Published As

Publication number Publication date
JP2016509059A (ja) 2016-03-24
CN105163740A (zh) 2015-12-16
WO2014130678A2 (en) 2014-08-28
WO2014130678A3 (en) 2014-11-20
KR20150141943A (ko) 2015-12-21
US20150374725A1 (en) 2015-12-31
EP2958567A2 (en) 2015-12-30
MX2015010765A (es) 2016-05-09
AU2014218903A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
KR100553294B1 (ko) 역류 억제제
RU2497512C2 (ru) Композиции на основе тапентадола для лечения боли
JP7246384B2 (ja) 遅延放出デフェリプロン錠剤及びその使用法
ES2408343A2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
KR102194174B1 (ko) 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손
US8460705B2 (en) Threo-DOPS controlled release formulation
CN109803684A (zh) 用于治疗肝细胞癌的组合疗法
JP2009514965A (ja) 代謝障害を制御するための組成物およびその使用方法
KR20080106991A (ko) 내장통 치료용 옥시코돈의 사용
CN103285015A (zh) 三尖杉碱口服剂型
HK1207563A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
HK1219868A1 (zh) 治疗和防治肠道损伤、紧密连接部功能障碍相关疾病的方法和组合物
KR20200140284A (ko) 비만대사 수술 환자에서의 칼시페디올의 용도
KR20030076692A (ko) 디클로페낙과 오르노프로스틸로 이루어지는 의약 조성물
US20060122275A1 (en) Agentfor reducing side effects of diclofenac
CA3182864A1 (en) Methods and compositions for treating chemotherapy-induced diarrhea
EP3870175A1 (en) Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis
JP2015003902A (ja) 血管新生阻害剤
WO2006046746A1 (ja) 内臓痛予防・治療剤
US20230088240A1 (en) Accelerating the drying rate of softgel capsules
US8158149B2 (en) Threo-DOPS controlled release formulation
CN118903067A (zh) 治疗肥胖症的方法
Özgüney Conventional and novel pharmaceutical dosage forms on prevention of gastric ulcers
WO2025008449A1 (en) Use of tryptophan hydroxylase 1 (tph1) inhibitors for the treatment of atherosclerosis
US20140322313A1 (en) Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist